Spyre Therapeutics, Inc. (SYRE) - Stock Analysis
Last updated: Jun 8, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Positive SPY001 Part A topline (announced 2026‑04‑13) and multiple SKYLINE/SKYWAY readouts staged across Q2–Q4 2026, alongside an upsized equity offering priced 2026‑04‑14 that extends cash runway, have pushed the stock ~50% above its 21‑day SMA; this fresh clinical win plus strong momentum make SYRE an event‑driven hot idea near term, though highly risky.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Debt-free Liquidity • Revenue Absence • Premium Valuation SYRE has an exceptionally strong, debt-free balance sheet and ample liquidity, but with no revenue, persistent losses, and a rich valuation, the stock looks fundamentally unsupported despite low solvency risk.
Price Behavior
Key Price Behavior Insights: • Low-70s support • Fast rebound • Nearby resistance Support Level: $71.5-$72.0 Resistance Level: $75.5-$78.5 SYRE is recovering and holding a developing low-70s support zone, but the fast rebound has pushed it into nearby $75.5-$78.5 resistance and leaves it vulnerable to a short pullback unless it stays above about $71.5-$72.
Sentiment & News
Key News Insights: • Trial Enrollment • Investor Outreach • Equity Grants Spyre Therapeutics advanced SPY072 as SKYWAY completed enrollment across all Phase II sub-studies, reinforcing steady clinical execution and investor momentum.
AI Summary
SYRE has shifted from a cash-rich biotech story to a real clinical catalyst play after SKYLINE's ulcerative colitis efficacy signal, but with the stock already pricing in success, the investment now hinges on near-term readouts proving the signal is durable across indications rather than just confirming a one-off data pop.
Description
Spyre Therapeutics is a preclinical biotechnology firm developing monoclonal antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Its lead program is an anti-α4β7 integrin IgG1 candidate, alongside antibody programs against TL1A and IL-23 and several combination regimens currently in preclinical evaluation. The company, incorporated in 2013 and renamed from Aeglea BioTherapeutics in November 2023, is based in Waltham, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 15 | Apr 22 | SYRE | Spyre Therapeutics, Inc. | Positive SPY001 Part A topline (announced 2026‑04‑13) and multiple SKYLINE/SKYWAY readouts staged across Q2–Q4 2026, alongside an upsized equity offering priced 2026‑04‑14 that extends cash runway, have pushed the stock ~50% above its 21‑day SMA; this fresh clinical win plus strong momentum make SYRE an event‑driven hot idea near term, though highly risky. | Closed | +5.8% |
| Feb 23 | Mar 2 | SYRE | Spyre Therapeutics, Inc. | Six clinical proof‑of‑concept readouts slated for 2026, reported cash runway into 2028 (~$757m cash/marketable securities) and a strong recent 21‑day move (~+26.8% with a one‑day +14% jump) give SYRE a clear event‑driven upside path; momentum traders can exploit this high‑risk setup ahead of Q2 SKYLINE Part A data and subsequent 2026 catalysts. | Closed | -3.8% |